 iStockAnalyst | Sanofi lets go of rights to Regeneron's antibodies in ophthalmology FierceBiotech The deal amends the collaboration between Sanofi and Regeneron for the antibodies that target receptors for platelet-derived growth factor (PDGF) and the angiopoietin2 (ANG2) receptor and ligand for eye ailments. Regeneron has agreed to pay Sanofi $10 ... Regeneron Gains Full Rights to Ophthalmology Antibodies from Sanofi in $65M+ ... Regeneron Acquires Rights to Two Families of Novel Antibodies UPDATE 1-Regeneron raises 2013 Eylea sales view, profit beats Street |
